Login / Signup
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
Nicola J Curtin
Yvette Drew
Sweta Sharma-Saha
Published in:
Nature reviews. Clinical oncology (2020)
Keyphrases
</>
dna damage
dna repair
stem cells
oxidative stress
mesenchymal stem cells
breast cancer risk
bone marrow
cell therapy